17

Abdel Aziz AM, Lehman GA. Pancreatitis after endoscopic retrograde cholangio-pancreatography. World J Gastroenterol 2007; 13(19):2655-68. [More details]

16

Lieb JG 2nd, Draganov PV. Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography. World J Gastroenterol 2007; 13(26):3567-74. [More details]

15

Kisli E, Baser M, Aydin M, Guler O. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis. Hepatogastroenterology 2007; 54(73):250-3. [More details]

14

Comi RJ. Octreotide: A 15-Year Update. Endocrinologist 2006; 16(2) 86-90. [More details]

13

Vila JJ, Jimenez FJ, Prieto C, Borobio E, Juanmartinena JF, Borda F. Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, non-randomized study. Gastroenterol Hepatol 2006; 29(4):231-6. [More details]

12

Barrie M, Klein SD, Brown CA, Edge MD, Affronti JA, Cai Q. Endoscopic retrograde cholangiopancreatography after a liquid fatty meal: effect on deep common bile duct cannulation time. Endoscopy 2006; 38(3):241-8. [More details]

11

Pungpapong S, Kongkam P, Rerknimitr R, Kullavanijaya P. Experience on endoscopic retrograde cholangiopancreatography at tertiary referral center in Thailand: risks and complications. J Med Assoc Thai 2005; 88(2):238-46. [More details]

10

Wu SD, Zhang ZH, Kong J, Li YJ, Jin JZ, Wang W, et al. Effects of somatostatin analogues on human sphincter of Oddi pressure. Hepatobiliary Pancreat Dis Int 2005; 4(2):302-5. [More details]

9

Wu SD, Zhang ZH, Jin JZ, Kong J, Wang W, Li DY, et al. Effects of different drugs on the sphincter of Oddi motility: study with choledochoscope manometry. Zhonghua Yi Xue Za Zhi 2005; 85(27):1911-5. [More details]

8

Poon RT. Reply to: Prevention of post-ERCP pancreatitis: are there any pearls for sale?. Gastroenterology 2004; 127(1):350. [More details]

7

Gottumukkala SR. Prevention of post-ERCP pancreatitis: are there any pearls for sale?. Gastroenterology 2004; 127(1):348-50. [More details]

6

Miao L, Fan ZN, Ji GZ, Wen W, Jiang GB, Wu P, et al. Endoscopic stent for palliating malignant and benign biliary obstruction. Chin J Cancer Res 2004; 16(2):118-22. [More details]

5

Boix E, Lopez P, Perez-Mateo M, et al. Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment. J Endocrinol Invest 2004; 27(6):613-4. [More details]

4

Piche T. Intravenous bolus somatostatin after endoscopic retrograde cholangiopancreatography with intended diagnosis reduced the incidence of acute pancreatitis: a randomized controlled trial. Hepato-Gastro 2004; 11(3):242-43. [More details]

3

Ostroff JW. Endoscopic and radiologic management of pancreatic and biliary tract diseases. Sem Gastrointest Dis 2003; 14(4):222-36. [More details]

2

Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 2003; 52(12):1768-73. [More details]

1

Freeman ML. Prevention of post-ERCP pancreatitis: Pharmacologic solution or patient selection and pancreatic stents?. Gastroenterology 2003; 124(7):1977-80. [More details]